Visit of WHO August 24th, 2022

Institut Pasteur de Tunis

130th anniversary
In 1893, Louis Pasteur entrusted his nephew Adrien Loir with the implementation of a vaccination center in Tunis. Thus, after that of Paris and Saigon was created by a Beylical decree, the Pasteur Institute of Tunis (IPT).

**Nobel Prize of Medicine:** In 1928 Charles Nicolle won the Nobel Prize in Physiology or Medicine for his work on typhus.

**Major discoveries on:**
- Typhus
- Toxoplasma
- Leishmaniasis
- Inapparent disease

Charles Nicolle the Director of IPT (1903-1936)
After the indépendance 1956

The IPT participates in the eradication of several endemic diseases in Tunisia such as malaria, shistosomiasis, trachoma and poliomyelitis. We contribute to the national vaccination campaigns (poliomyelitis, etc.) and to the development of public health programs.

After 1995

The IPT changes status and becomes a “Etablissement public de Santé” with an administrative board and a scientific board, which allows him to reorganize and reinforce its research and development activities.
Missions and authorities

Ministry of Health

Diagnosis
23 Diagnostic Laboratories

Research and training
10 Research Laboratories
4 Specialized Units

Bio-production
Sera and Vaccines production unit

Ministry of Higher Education and Scientific Research
University Tunis El-Manar
Institut Pasteur de Tunis

- Administrative board: (16 members)
- Scientific board: DG + 8 elected members from IPT (+4 international experts)

- Ethics
- Training and internship
- Health and biosafety
- Bioresources
- Quality control

- BSL3
- OMICS platform
- Animal facility
- FACS Flow facility
- Clinical Investigation Center (CIC)
Research Support Services

Valorization and Technological Transfer Unit

Scouting and projects support

Communication, Science and Society Unit

Technological platform

Valorization and Technological Transfer Unit

Scouting and projects support

Communication, Science and Society Unit

Technological platform

PMO

CVT2

UNISS

IPTOMICS

WHO- mRNA Meeting
April, 2023

WHO- mRNA Meeting
April, 2023
Overall workforce: 527

- Scientists; 140
- Administratifs; 116
- Technicians/Engineers 113
- Paramedic staff; 65
- Workers; 93

Source: Social Report of the Institut Pasteur de Tunis, 2022
23 laboratories: Cover the full array of clinical biology tests. IPT is recognized for the expertise of some of the laboratories in the specialized medical biology.

Several national (rabies, poliomyelitis, measles, bacteria, other) or international reference centers (EMRO/WHO: for poliomyelitis, measles, and HPV).

IPT is a center for vaccination (for the travelers) and a center for rabies treatment (free).
The Unique Bio-production unit of vaccines and sera in the country

700 m² dedicated to Bio-production

(BCG: Since 1927-1999)

From 2004: Application of international standards
Our products

**BCG vaccine**
- BCG + solvant
- Immune BCG

**Therapeutic sera**
- Anti-scorpions: *Androctonus australis, Buthus occitanus*
- Anti-vipera: *Cerastes cerastes, Vipera lebetina*
- Anti-rabies
Products Sales (doses)

- Vaccin BCG intradermique: 18420, 19890, 18680
- BCG frais pour immunothérapie: 13050, 10696, 12669
- Sérums antiscorpionique: 151, 5510, 2742
- Sérums antivipéris: 840, 1380, 360
- Sérums antirabique: 1010, 3930, 0

TOTAL:
- 2020: 33471
- 2021: 34451
- 2022: 41406
Training Activities

IPT is affiliated to the University of Tunis El Manar: Supervision of graduate and post-graduate students

Organization of theoretical and hands-on practice training courses

WHO-TDR training center
Main Funding agencies

- European Commission
- National Institutes of Health
- Wellcome
- EPFL
- World Health Organization
- Institut Pasteur
- INSTITUT MERIEUX
- Ministère de l'Enseignement Supérieur, de la Recherche Scientifique
Early during the pandemic:
- Taskforce of mRNA vaccine
- Benchmarking
- PPP

Tunisia: Spoke (Feb 2022)

<table>
<thead>
<tr>
<th>Training</th>
<th>Organisation</th>
<th>Date</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introductory Course for Biologics Development and Manufacturing</td>
<td>(IVI)/WHO</td>
<td>July, 2022</td>
<td>2</td>
</tr>
<tr>
<td>Introductory Training Course for Standard Practices (GxP)&quot;</td>
<td>IVI/WHO</td>
<td>Oct- Nov, 2022</td>
<td>2</td>
</tr>
<tr>
<td>NIBRT Aseptic Behaviours Course</td>
<td>WHO</td>
<td>Online</td>
<td>6</td>
</tr>
<tr>
<td>Biotech Training Facility, Leiden, Netherlands</td>
<td>WHO</td>
<td>Dec 2022</td>
<td>4</td>
</tr>
<tr>
<td>ICGB, Italy</td>
<td>WHO</td>
<td>Dec 2022</td>
<td>2</td>
</tr>
<tr>
<td>AFRIGEN</td>
<td></td>
<td>Dec 2022</td>
<td>4</td>
</tr>
</tbody>
</table>

Preclinical study of mRNA vaccine against

- Leishmaniasis
- Rabies

Pr. Melika Ben Ahmed
(Thursday 11h30-12)
VISION: From Insightful Science to Innovative Health: Strengthening Translational Capacity and Talent Interoperability in Vaccine and Biologic Research & innovation

ERA-Talent project Process for development of vaccine & biologics

[Diagram showing the process of research and development]
Thank you for your attention